Investigating Injectability of High Concentration mAb Formulations with VROC Technology

In this presentation, we explore the critical role of viscosity in developing high-concentration monoclonal antibody (mAb) formulations (≥ 100 mg/mL) for subcutaneous injection.

To improve patient experience and compliance, these biotherapeutics must be suitable for injectability, which must further be explored by measuring their non-Newtonian behavior at representative shear rates during injection.

We demonstrate the use of RheoSense VROC technology for the accurate screening of formulation candidates using small sample volumes (< 200 µL). By generating comprehensive viscosity profiles over a wide shear rate range, this method allows for the effective identification and selection of viable candidates with optimal viscosity for subcutaneous delivery, ensuring proper therapeutic development.